Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-06-07
2005-06-07
Krass, Frederick F. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S922000
Reexamination Certificate
active
06903130
ABSTRACT:
A use of (S)-(−)-α-ethyl-2-oxo-1-pyrrolidineacetamide for the manufacture of a medicament for treatment of particular disease and new pharmaceutical compositions comprising (S)-(−)-α-ethyl-2-oxo-1-pyrrolidineacetamide.
REFERENCES:
patent: 4696943 (1987-09-01), Gobert et al.
patent: 5998380 (1999-12-01), Ehrenberg et al.
patent: 6195601 (2001-02-01), Spillner et al.
patent: 6495601 (2002-12-01), Hochman
patent: 0162036 (1985-11-01), None
patent: 0 408 782 (1991-01-01), None
patent: 0408782 (1991-01-01), None
patent: WO 99/31075 (1999-06-01), None
patent: WO 99/37296 (1999-07-01), None
Fraser, et al., Effects of Anti-epileptic Drugs in Glutamine Synthetase Activity in Mouse Brain, British Journal of Pharmacology Apr., 1999, vol. 126, pp. 1634-1638.
J. Prous, et al.; “Levetiracetam”Drugs of the Future, ES, Barcelona, vol. 19, No. 2, 1994, pp. 111-113.
Wilson, et al; “New Antiepileptic Drugs”;Balliere's Clinical Neurology, London, GB, vol. 5, No. 4, Dec. 1996, pp. 723-747.
H.G. Wiesser; “Treatment of epilepsies: current situation”; Schweizerische Rundschau for Medizin (PRAXIS), vol. 85, No. 4 (1996), pp. 74-79. (Translation included).
American Psychiatric Association; American Psychiatric Association Releases a Treatment Guieline for Bipolar Disease; American Family Physician, vol. 51, No. 6, 1995, pp. 1605-1609.
Post, Robert; “Comparative Pharmacology of Bipolar Disorder and Schizophrenia”;Schizophrenia Research; vol. 39, No. 2, Sep. 29, 1999, pp. 153-158.
Patsalos, P.N.; “Pharmacokinetic profile of levetiracetam; toward ideal characteristics”;Pharmocology&Theraeputics, vol. 85 (2000); pp. 77-85.
M. Bialer, et al; “Progress report on new antiepileptic drugs: a sunmary of the Third Eilat Conference”;Epilepsy Research; vol. 25 (1996); pp. 229-319.
Marcotte, D.; Use of topirmate, a new anti-epileptic as a mood stabilizer;Journal of Affective Disorders; vol. 50 (1998), pp. 245-251.
Klitgaard Henrik
Lamberty Yves
Matagne Alain
Waegemans Tony
Krass Frederick F.
UCB S.A.
LandOfFree
Pyrrolidineacetamide derivative alone or in combination for... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pyrrolidineacetamide derivative alone or in combination for..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyrrolidineacetamide derivative alone or in combination for... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3509200